Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741425 | 0.89 | F2 (0.41) | F2PRSS1TAS1R3TAS1R1P2RX7 | |
| SCHEMBL6738372 | 0.88 | F2 (0.47) | F2PRSS1TAS1R3TAS1R1P2RX7 | |
| SCHEMBL6740609 | 0.86 | F2 (0.41) | F2PRSS1TAS1R3TAS1R1P2RX7 | |
| SCHEMBL5158169 | 0.85 | F2 (0.42) | F2PRSS1TAS1R3TAS1R1 | |
| SCHEMBL6996811 | 0.85 | F2 (0.50) | F2PRSS1TAS1R3TAS1R1 | |
| SCHEMBL6741110 | 0.84 | F2 (0.43) | F2PRSS1TAS1R3TAS1R1P2RX7 | |
| Hydrochloric Acid SCHEMBL7978158 | 0.84 | F2 (0.49) | F2PRSS1TAS1R3TAS1R1 | |
| SCHEMBL6735050 | 0.81 | F2 (0.42) | F2PRSS1P2RX7 | |
| SCHEMBL6738751 | 0.81 | F2 (0.40) | F2PRSS1P2RX7 | |
| SCHEMBL6739928 | 0.81 | F2 (0.42) | F2PRSS1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686358-B2 | ANTICOAGULANTS; CARDOVISCULAR DISORDERS | LES LABORATOIRES SERVIER (FR) | 2004-02-03 | — | — | US | claimed |
| US-20020111341-A1 | Bicyclic amino-pyrazinone compounds | LES LABORATOIRES SERVIER (FR) | 2002-08-15 | — | — | US | claimed |
| EP-1215213-A2 | Bicyclic amino-pyrazone derivatives, their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-06-19 | — | — | EP | claimed |
| US-6686358-B2 | ANTICOAGULANTS; CARDOVISCULAR DISORDERS | LES LABORATOIRES SERVIER (FR) | 2004-02-03 | — | — | US | disclosed |
| US-20020111341-A1 | Bicyclic amino-pyrazinone compounds | LES LABORATOIRES SERVIER (FR) | 2002-08-15 | — | — | US | disclosed |
| EP-1215213-A2 | Bicyclic amino-pyrazone derivatives, their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111341-A1 | Bicyclic amino-pyrazinone compounds | CTRL, PRSS3, PRSS1 | F2 125/4885PRSS1 3/4885TAS1R3 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.